FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1705-1715 October 25, 2007 Number 17 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy.

Methods We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival.

Results With a minimum of 2 years of follow-up (3 years for 69% of patients), significantly more patients survived in the TPF group than in the PF group (hazard ratio for death, 0.70; P=0.006). Estimates of overall survival at 3 years were 62% in the TPF group and 48% in the PF group; the median overall survival was 71 months and 30 months, respectively (P=0.006). There was better locoregional control in the TPF group than in the PF group (P=0.04), but the incidence of distant metastases in the two groups did not differ significantly (P=0.14). Rates of neutropenia and febrile neutropenia were higher in the TPF group; chemotherapy was more frequently delayed because of hematologic adverse events in the PF group.

Conclusions Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy. (ClinicalTrials.gov number, NCT00273546 [ClinicalTrials.gov] .)

Source Information

From the Dana–Farber Cancer Institute, Boston (M.R.P., R.B.T., A.D.C., C.M.N., R.I.H.); Sanofi-Aventis, Malvern, PA (D.M.H.); Hospital Iturraspe, Santa Fe (C.R.B., R.C.V.), and Instituto Angel H. Roffo, Buenos Aires (E.M., B.R.) — both in Argentina; London Regional Cancer Centre, London, ON, Canada (E.W., V.V.); Cancer Research Center, Moscow (V.G., S.T., I.R.); Emory Winship Cancer Institute, Atlanta (D.M.S.); University of Maryland Greenebaum Cancer Center, Baltimore (K.C.); Maine Center for Cancer Medicine and Blood Disorders, Scarborough, ME (T.J.E., M.D.); Vanderbilt University (B.A.M.) and Metro Nashville General Hospital (A.C.) — both in Nashville; Sylvester Cancer Center, University of Miami, Miami (L.E.R., A.M.M.); University of Virginia, Charlottesville (R.B.C., P.W.R.); Veterans Affairs Western New York Healthcare System, Buffalo (M.S., L.S.); University of Pittsburgh, Pittsburgh (S.A.); and Vincent Lombardi Cancer Center, Washington, DC (K.W.H.).

Address reprint requests to Dr. Posner at the Dana–Farber Cancer Institute, 44 Binney St., SW 430, Boston, MA 02115, or at marshall_posner{at}dfci.harvard.edu.

Full Text of this Article

Related Letters:

Treatment of Head and Neck Cancer
Forastiere A., Weber R., Ang K., Trotti A. III, Pajak T. F., Ridge J. A., Saghir F., Feldman L. E., Nutting C. M., Bhide S. A., Harrington K. J., Posner M. R., Haddad R. I., Tishler R. B.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1076-1078, Mar 6, 2008. Correspondence

This article has been cited by other articles:

• Koh, Y., Kim, T. M., Jeon, Y. K., Kwon, T.-K., Hah, J. H., Lee, S.-H., Kim, D.-W., Wu, H.-G., Rhee, C.-S., Sung, M.-W., Kim, C. W., Kim, K. H., Heo, D. S. (2009). Class III {beta}-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 0: mdp002v1-mdp002 [Abstract] [Full Text]  
• Posner, M. R., Norris, C. M., Wirth, L. J., Shin, D. M., Cullen, K. J., Winquist, E. W., Blajman, C. R., Mickiewicz, E. A., Frenette, G. P., Plinar, L. F., Cohen, R. B., Steinbrenner, L. M., Freue, J. M., Gorbunova, V. A., Tjulandin, S. A., Raez, L. E., Adkins, D. R., Tishler, R. B., Roessner, M. R., Haddad, R. I., for the TAX 324 Study Group, (2009). Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 20: 921-927 [Abstract] [Full Text]  
• Licitra, L., Felip, E., On behalf of the ESMO Guidelines Working Group, (2009). Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv121-iv122 [Full Text]  
• Holsinger, F. C., Kies, M. S., Diaz, E. M. Jr, Gillenwater, A. M., Lewin, J. S., Ginsberg, L. E., Glisson, B. S., Garden, A. S., Ark, N., Lin, H. Y., Lee, J. J., El-Naggar, A. K., Ki Hong, W., Shin, D. M., Khuri, F. R. (2009). Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. JCO 27: 1976-1982 [Abstract] [Full Text]  
• Pointreau, Y., Garaud, P., Chapet, S., Sire, C., Tuchais, C., Tortochaux, J., Faivre, S., Guerrif, S., Alfonsi, M., Calais, G. (2009). Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation. JNCI J Natl Cancer Inst 101: 498-506 [Abstract] [Full Text]  
• Ashimori, N., Zeitlin, B. D., Zhang, Z., Warner, K., Turkienicz, I. M., Spalding, A. C., Teknos, T. N., Wang, S., Nor, J. E. (2009). TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Molecular Cancer Therapeutics 8: 893-903 [Abstract] [Full Text]  
• Diaz, R., Blakey, M. D., Murphy, P. B., Cryar, A. K., Cmelak, A. J. (2009). Thyroid Storm After Intensity-Modulated Radiation Therapy: A Case Report and Discussion. The Oncologist 14: 233-239 [Abstract] [Full Text]  
• Lefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., Licitra, L., Lunghi, F., Stupp, R., Lacombe, D., Bogaerts, J., Horiot, J. C., Bernier, J., Vermorken, J. B., for the EORTC Head and Neck Cancer Cooperative Gro, (2009). Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. JNCI J Natl Cancer Inst 101: 142-152 [Abstract] [Full Text]  
• Forastiere, A. A., Trotti, A. M. (2009). Searching for Less Toxic Larynx Preservation: A Need for Common Definitions and Metrics. JNCI J Natl Cancer Inst 101: 129-131 [Full Text]  
• Hui, E. P., Ma, B. B., Leung, S. F., King, A. D., Mo, F., Kam, M. K., Yu, B. K., Chiu, S. K., Kwan, W. H., Ho, R., Chan, I., Ahuja, A. T., Zee, B. C., Chan, A. T. (2009). Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma. JCO 27: 242-249 [Abstract] [Full Text]  
• Beitler, J. J., Cooper, J. S. (2009). Seduction by Induction?. JCO 27: 9-10 [Full Text]  
• Nakajima, O., Matsunaga, A., Ichimaru, D., Urata, Y., Fujiwara, T., Kawakami, K. (2009). Telomerase-specific virotherapy in an animal model of human head and neck cancer. Molecular Cancer Therapeutics 8: 171-177 [Abstract] [Full Text]  
• Tanvetyanon, T., Eikman, E. A., Sommers, E., Robinson, L., Boulware, D., Bepler, G. (2008). Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer. JCO 26: 4610-4616 [Abstract] [Full Text]  
• Salama, J. K., Stenson, K. M., Kistner, E. O., Mittal, B. B., Argiris, A., Witt, M. E., Rosen, F., Brockstein, B. E., Cohen, E. E. W., Haraf, D. J., Vokes, E. E. (2008). Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 19: 1787-1794 [Abstract] [Full Text]  
• Haddad, R. I., Shin, D. M. (2008). Recent Advances in Head and Neck Cancer. NEJM 359: 1143-1154 [Full Text]  
• Glynne-Jones, R., Mawdsley, S. (2008). Anal Cancer: The End of the Road for Neoadjuvant Chemoradiotherapy?. JCO 26: 3669-3671 [Full Text]  
• Ang, K. K. (2008). Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes. The Oncologist 13: 899-910 [Abstract] [Full Text]  
• Singh, B., Pfister, D. G. (2008). Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge?. JCO 26: 3114-3116 [Full Text]  
• Adelstein, D. J. (2008). Redefining the Role of Induction Chemotherapy in Head and Neck Cancer. JCO 26: 3117-3119 [Full Text]  
• Yoo, G. H., Subramanian, G., Piechocki, M. P., Ensley, J. F., Kucuk, O., Tulunay, O. E., Lonardo, F., Kim, H., Won, J., Stevens, T., Lin, H.-S. (2008). Effect of Docetaxel on the Surgical Tumor Microenvironment of Head and Neck Cancer in Murine Models. Arch Otolaryngol Head Neck Surg 134: 735-742 [Abstract] [Full Text]  
• Marur, S., Forastiere, A. A. (2008). Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 83: 489-501 [Abstract] [Full Text]  
• Bolke, E., Peiper, M., Gripp, S., Vermorken, J. B. (2008). Chemotherapy in Unresectable Head and Neck Cancer. NEJM 358: 1075-1075 [Full Text]  
• Forastiere, A., Weber, R., Ang, K., Trotti, A. III, Pajak, T. F., Ridge, J. A., Saghir, F., Feldman, L. E., Nutting, C. M., Bhide, S. A., Harrington, K. J., Posner, M. R., Haddad, R. I., Tishler, R. B. (2008). Treatment of head and neck cancer.. NEJM 358: 1076-1076 [Full Text]  
• Kies, M. S., Blumenschein, G. R. Jr., Rosenthal, D. I. (2008). Sequential Chemoradiation for Squamous Cell Carcinoma of the Head and Neck. Am Soc Clin Oncol Ed Book 2008: 235-238 [Abstract] [Full Text]  
• Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., van den Weyngaert, D., Awada, A., Cupissol, D., Kienzer, H. R., Rey, A., Desaunois, I., Bernier, J., Lefebvre, J.-L., the EORTC 24971/TAX 323 Study Group, (2007). Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. NEJM 357: 1695-1704 [Abstract] [Full Text]